Curated News
By: NewsRamp Editorial Staff
June 10, 2026

Onco-Innovations Advances ONC010 Drug Candidate with Scale-Up Milestone

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon
Original Source

TLDR

  • Onco-Innovations advances ONC010 toward clinical trials, potentially gaining a first-mover advantage in targeted solid tumour treatment.
  • Onco-Innovations scales up A83B4C63 production with Dalton Pharma Services to optimize yield and reproducibility for regulatory readiness.
  • Onco-Innovations' progress on ONC010 brings hope for more effective cancer treatments, improving patient outcomes and quality of life.
  • Dalton Pharma Services collaborates with Onco-Innovations to scale up a patented drug candidate targeting solid tumours.

Impact - Why it Matters

This development matters because Onco-Innovations is moving closer to clinical trials for ONC010, a potential treatment for solid tumors. Solid tumors are notoriously difficult to treat, and new therapies are urgently needed. The scale-up of the active pharmaceutical ingredient A83B4C63 ensures that the company can produce enough high-quality drug for studies and eventual patient use. For investors, this progress signals that Onco-Innovations is executing on its CMC strategy, de-risking the path to IND filing and human trials. For patients, it brings hope for a novel approach to combatting solid tumors. The collaboration with Dalton Pharma Services also adds credibility, as Dalton is a reputable contract development and manufacturing organization.

Summary

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced a significant step forward in its drug development pipeline. The company has initiated process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This milestone is part of Onco-Innovations' chemistry, manufacturing, and controls (CMC) strategy, aimed at advancing toward IND-enabling studies and first-in-human clinical trials. The program focuses on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates. The work is being conducted in collaboration with Dalton Pharma Services to establish a robust, scalable manufacturing process that can support preclinical development, regulatory readiness, and future clinical supply needs.

Onco-Innovations is a Canadian-based oncology company dedicated to cancer research and treatment. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. Its mission is to pursue the prevention and treatment of cancer through innovative solutions. The scale-up of ONC010 represents a critical step toward bringing a potential new therapy to patients. The company's focus on solid tumors addresses a significant unmet medical need, as these cancers account for the majority of cancer cases and deaths worldwide.

This news was disseminated through NetworkNewsWire (NNW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN. NNW provides financial news and content distribution for companies and the investment community, offering services such as press release distribution, editorial syndication to 5,000+ outlets, and social media distribution. The full press release is available at https://nnw.fm/kfFWv. For more information about Onco-Innovations, visit https://oncoinnovations.com/.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Advances ONC010 Drug Candidate with Scale-Up Milestone

blockchain registration record for this content.